09:49 AM EST - Oncolytics Biotech Inc. : Announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with previously treated advanced or metastatic non-small cell lung cancer. The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.06 at $0.72.
